Inventor · disambiguated record
Robert C. Wild
Also filed as: WILD ROBERT · WILD ROBERT C · WILD ROBERT CHRISTIAN
3 granted patents·7 pending applications·2 citations·filing 2010–2021
50Inventor score
Top patents by PatentIndex Score
10 records- 0164US8642834B2Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formationKAN JULIE·Filed 2010·Granted Feb 4, 2014·2 cites·7 claims
- 0245US2023372294A1Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for subcutaneous administration and the use thereofDRACEN PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0340US2022332676A1Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereofDRACEN PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0438US2011171124A1In situ methods for monitoring the EMT status of tumor cells in vivoOSI PHARM INC·Filed 2010·Application pending·0 cites
- 0537US2022117938A1Combinaton therapy with a don prodrug and an immune checkpoint inhibitorDRACEN PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0636US12240797B2Method of preparing a DON prodrug from L-glutamic acidDRACEN PHARMACEUTICALS INC·Filed 2020·Granted Mar 4, 2025·0 cites·20 claims
- 0733US11760723B2Method of preparing a DON prodrug from L-pyroglutamic acidDRACEN PHARMACEUTICALS INC·Filed 2020·Granted Sep 19, 2023·0 cites·20 claims
- 0833US2013137975A1Pet imagingBUGAJ JOSEPH E·Filed 2011·Application pending·0 cites
- 0928US2012128670A1mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPYBARR SHARON M·Filed 2010·Application pending·0 cites
- 1022US2012064072A1Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R InhibitorFRANKLIN MARYLAND·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert C. Wild files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →